Rani Therapeutics
RANI
34 hedge funds and large institutions have $10.9M invested in Rani Therapeutics in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 2 closing their positions.
57% more capital invested
Capital invested by funds: $6.96M → $10.9M (+$3.96M)
0.15% more ownership
Funds ownership: 12.57% → 12.71% (+0.15%)
0% more funds holding
Funds holding: 34 → 34 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $27K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Simplex Trading
Chicago,
Illinois
|
+$18.3K |
| 2 |
Morgan Stanley
New York
|
+$9.95K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.34K |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$3.93K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$18 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$215K |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
-$212K |
| 3 |
Millennium Management
New York
|
-$100K |
| 4 |
ASGS
Alpha Square Group S
New York
|
-$64.7K |
| 5 |
Renaissance Technologies
New York
|
-$16.9K |
RANI Hedge Fund Activity: Q4 2023 in Review
34 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Rani Therapeutics (RANI) for Q4 2023, worth a combined $10.9M — up 57% from $6.96M a quarter earlier.
Fund positioning in RANI was balanced in Q4 2023: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 7 trimmed.
The largest buyer was Simplex Trading, adding an estimated $18.3K. The largest seller was Bank of America, cutting an estimated $215K.
- 34 institutional investors held Rani Therapeutics (RANI) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $10.9M of Rani Therapeutics stock for Q4 2023, up 57% quarter-over-quarter.
- 2 funds opened new Rani Therapeutics positions in Q4 2023 and 2 closed out, a net change of 0 holders.
- The largest Rani Therapeutics buyer in Q4 2023 was Simplex Trading, an estimated $18.3K added.
- The largest Rani Therapeutics seller in Q4 2023 was Bank of America, an estimated $215K sold.
Based on aggregated 13F filings for Q4 2023.